

16-JUN-2024 6:11
OPEN STUDIES IRB REPORT

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
BREAST	S1706	Breast, Inflammatory, RT +/- Olaparib	12-SEP-18	224	103
	S2007	Breast, Brain Mets, Sacituzumab Govitecan	15-DEC-20	194	67
	S2206	Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva	30-OCT-23	319	99
	S2212	Breast, TNBC, Neoadj Chemo + Pembro	21-JUL-23	291	119
	A011801	BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib	06-JAN-21	415	201
	A012103	Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab	03-MAY-23	326	154
	EA1211	Breast, HER2+, NeoAdj Therapy	10-MAY-23	1	3
	MA39	BREAST, Node-Pos, Reg RT vs No Reg RT	30-MAY-18	369	140
	NRGBR007	Breast, Stg I, De-Escalation of Breast RT	07-JUN-21	368	165
	NRGBR009	Breast, EarlyStg, Adjuvant Chemo	31-AUG-23	139	60
	CCD	S1703	Met Breast, STM-monitoring v Usual Care	16-JUL-18	216
S1912CD		CREDIT, Fin Counseling to reduce Fin Hardship	26-JUL-21	170	68
S2108CD		Genomic Tumor Board vs Usual Practice	22-AUG-22	24	29
A191901		Brst, Text/Motivational Intervention ET Adher	10-DEC-20	179	88
NHLBIMDS		LEUK, National MDS Study	05-APR-16	180	86
ERLYTX	S2012	Small Cell NEC, Stg IV, Combo Chemo +/- Atezo	02-DEC-21	180	71
	A071401	Prog Meningiomas,SMO/AKT/NF2 Inhib	28-AUG-15	255	92
	AGCT1531	Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult	08-MAY-17	180	116
	EAY191	ComboMATCH	06-MAR-23	251	109
	EAY191-S3	ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib	06-MAR-23	181	62
	EAY191A3	ComboMATCH-RAS-Mutant, All Stg, Palbo+Benim	15-NOV-23	81	37
	EAY191E4	ComboMATCH-Pr. Tax-Tx Tumors, Pac+Nilotinib	07-JUN-23	135	57
GI	S1922	Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect	16-DEC-19	158	54
	S2001	Rando II, Mets Pancreas , BRCA1/2, Comb Chemo	04-DEC-20	195	80
	S2104	Panc,Resect High-risk,Postop Adj Chemo vs Obs	14-OCT-21	173	58
	S2107	Colorectal, BRAF mut, Enc + CET +/-Nivo	06-JUN-22	163	66
	S2303	Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo	06-MAY-24	30	15
	A021806	Pancreas, Perioperative vs Adjuvant Chemo	01-JUL-20	258	118
	A022001	PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM	16-MAR-22	58	25
	A022004	Colon, Stg II-III, Encor+Cetux vs SOC	30-MAY-23	1	5
	A022102	Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/- Nivo	11-JAN-23	217	89
	A022104	Rectal, Loc Adv, Triplet vs Doublet Chemo	09-NOV-22	336	131
	EA2174	Esoph, Peri-Op Nivolumab +/- Ipilimumab	17-JAN-19	227	90

16-JUN-2024 6:11
OPEN STUDIES IRB REPORT

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	EA2176	Anal, Met, Immune Check Pt Inhibition + Chemo	15-OCT-20	212	88
	EA2182	Anal, Erly, DECREASE	12-NOV-19	293	96
	EA2192	Panc, APOLLO	29-APR-21	145	84
	EA2197	Gal, Rando Perioperative TX	22-DEC-20	126	68
	NRGGI004	Colorectal, Stg IV, dMMR Immuno-Therapy	07-NOV-17	315	114
	NRGGI008	Colon, Stg III, Adj Chemo	10-MAR-22	412	171
GU	S1802	Pros, Stg IV, SST +/- Surg/RT to Primary Tum	17-SEP-18	330	138
	S1931	RENAL, Stg IV, IO + Nephrectomy. vs IO Only	16-NOV-20	207	78
	S1937	Blad, Mets, Eribulin + Gem vs SOC	16-FEB-21	219	76
	S2200	pRCC, Adv, Cabo +/- Atezo	19-SEP-22	138	57
	S2210	Pros, High Risk, BRCA, Neoadj Carbo	14-AUG-23	126	38
	A031701	Bladder, ddGC for MIBC with DDR Tumor Alt	01-AUG-18	144	51
	A031702	GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC)	12-APR-19	228	92
	A031801	GU, mRCC, Cabozantinib +/- Radium-223	13-DEC-19	86	36
	A031803	Blad, NMIBC, Gemcitabine + MK-3475	06-JAN-20	128	56
	A032103	Urothelial, All Stg, MRD-Based Adj Tx	09-JAN-24	130	43
	EA8134	Penile, Local Adv, ILND +/- Chemo or ChemoRT	08-SEP-17	33	15
	EA8171	PROS, newly diagnosed, mpMRI for pre-op stagi	09-JUL-18	88	48
	EA8191	Pros, Local vs Systemic Thrpy	08-OCT-20	186	62
	EA8192	Blad, High Grade UTUC, Durv + Chemo	06-MAY-21	145	54
	EA8212	Blad, NMIBC, BRIDGE	01-DEC-22	126	71
	NRGGU008	Pros,Node+, Abiraterone acetate + Apalutamide	05-MAR-20	228	85
	NRGGU009	Pros, PREDICT-RT	15-DEC-20	434	160
	NRGGU010	Pros, Parallel De-Intens & Intens Trials	03-NOV-21	441	171
	NRGGU011	Pros, Dbl Blinded RT +/- Androgen Dep Tx	08-DEC-21	198	73
	NRGGU012	Renal, Stg IV, Stereo Abl Rad Therapy	30-JUN-22	199	63
	NRGGU013	Prostate, High-Risk, Five Fraction Radiation	13-NOV-23	0	3
LEUK	S1905	T-ALL/T-LBL, Rel/Ref, OBI-3424	17-AUG-20	60	25
	S1925	CLL/SLL, Newly Dx HR, Early vs Delayed V+O	14-DEC-20	240	97
	A041501	B-Cell ALL, Frontline Tx +/- Intuzumab Ozo	01-JUN-17	222	84
	A041701	AML, Age 60+, Conv Chemo +/- Uproleselan	16-JAN-19	173	62
	A041703	ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat	16-NOV-18	128	53
	A042001	B-Cell ALL, Inotuzunab+chemo v Standard chemo	27-FEB-23	118	44
	EA9152	ALL, T/B-Cell, Venetoclax + Vincristine	26-APR-18	51	23
	EA9171	CML, Anti-PD-1 Pembrolizumab + TKIs	03-OCT-18	83	38
	EA9181	ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab	14-OCT-20	168	60

**16-JUN-2024 6:11
OPEN STUDIES IRB REPORT**

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	EA9213	T-ALL, dara-hyal for chemo refractory MRD	16-JUN-22	46	16
	MM1YA-S01	AML, High Risk, Age <60, 7+3 vs experimental	16-MAY-24	18	6
	MYELOMATCH	MSRP for the NCI myeloMATCH Clinical Trials	16-MAY-24	30	12
LUNG	S1827	SCLC, MRI Surveillance +/- PCI	10-JAN-20	326	127
	S1900E	KRAS G12C: Sotorasib (AMG 510)	02-APR-21	312	126
	S1900G	EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu	03-APR-23	253	98
	S1900K	MET Exon 14: Tepotinib +/- Ramucirumab	18-DEC-23	209	80
	S1914	NSCLC, High Risk Early Stg, SBRT +/- Atezo	25-MAR-20	354	125
	S1933	NSCLC, Stg II-III, RT + Atezo	15-JUN-20	109	42
	S2302	NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC	06-MAR-23	450	185
	A081801	ALCHEMIST4, ALK and EGFR negative, Chemo-IO	03-JUN-20	402	172
	A082002	Lung, Adv, Systemic Tx +/- SBRT	21-DEC-21	175	61
	A151216	ALCHEMIST0 - screening	18-AUG-14	500	237
	EA5162	NSCLS,StgIV/IIB,EGFR exon20 insertion,AZD9291	05-APR-18	76	38
	EA5182	NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291	22-OCT-20	175	80
	LUNGMAP	NSCLC, Adv, Master	28-JAN-19	413	177
	NRGLU008	Lung NSCL, StgII-III, StereoBodyRad/MedChemo	10-MAY-23	23	8
LYMPH	S1608	FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob	10-AUG-17	189	71
	S1918	DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP	19-MAR-21	174	70
	S2114	NHL, Rel/Ref, CD19 CAR-T +/- Consolidation	23-FEB-23	125	40
	S2207	LBCL, Transplant Inelig, Targeted Tx + Tafa	30-JUN-23	96	33
	A051902	PTCL,CHO(E)PvCC-486-CHO(E)PvDuvetlisib-CHO (E)P	30-JUL-21	160	71
	A052101	Lymph, Stg I-IV, Cont v Intermittent Zanub	08-SEP-23	191	70
	AHOD2131	cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy	28-APR-23	174	107
	ANHL1931	PMBCL, Chemo-Immunotherapy +/- Nivo	07-JUN-21	217	105
	E4412	HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin	24-JAN-14	90	56
	EA4151	Lymph, AHCT +/-Ritux, MRD Neg	29-AUG-17	232	81
MELAN	S2000	MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo	23-SEP-20	112	45
	S2015	MELAN, Stg I-II, 1cm v 2cm excision margins	08-APR-22	157	65
	A091903	Melan, Resected Mucosal, Adj Nivo +/- Cabo	01-JUN-22	94	52
	EA6141	Melan, Adv, Nivolumab+Ipi ± Sargmostim	10-SEP-15	240	94
	EA6174	Merkel, Adjuvant Pembrolizumab vs Observation	23-JUL-18	306	104

16-JUN-2024 6:11
OPEN STUDIES IRB REPORT

06:11 Sunday, June 16, 2024 4

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	EA6192	Melan, Adv, Erly Discont of Antibdy Thrpy	27-AUG-20	114	49
	EA6194	Melan, Stage IIIB-D, Pembro +/- CMP-001	19-MAR-21	1	3
MMYEL	S1803	MM, Maintenance, Len vs Len/Dara	27-JUN-19	315	127
	S2209	MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D	30-MAY-23	177	68
	S2213	AL Amyloidosis, Newly Dx, Dara-VCD v ASCT	01-DEC-23	79	27
	EAA173	MYEL, SMM, Rd +/- Daratumumab	30-APR-19	228	97
	EAA181	Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE)	27-OCT-20	200	86
MULT	S2101	Melan or HNSCC, Adv, Cabo + Nivo	14-OCT-22	162	65
OTHER	A071701	BRAIN, Met, Geno-guided trial	15-AUG-19	212	73
	A071702	BRAIN, Blockade Tx in Recurrent Glioblastoma	30-OCT-20	146	69
	A092104	Uter,Adv, Olaparib+Temozolomide vs Inv Choice	09-DEC-22	156	60
	A092107	DDLPS. Palbocicli v Palbociclib+Cemiplimab	24-MAR-23	44	11
	A151804	irAEs, National Biorepository to Adv Studies	31-JAN-20	143	76
	ARST2031	RMS, Stg IV, VINO-AC+VINO-CPO vs VAC+VINO-CPO	13-SEP-21	183	94
	CCTGHN11	HN, All Stg, Guided Elec Contra Neck Tx	29-SEP-22	58	18
	EA3132	HN SCC, Stg III-IV , Adj RT +/- Cisp	29-MAR-16	214	69
	EA3161	HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo	20-JUN-19	236	94
	EA3191	HN, High Risk HNSCC, Adj +/- Pembro	08-JAN-21	190	69
	NRGBN003	Mening, Grd II, Observation vs Irradiation	14-JUN-17	255	90
	NRGBN011	Brain, Lomustine + Temo vs Temo	29-NOV-21	263	98
	NRGBN012	Brain, Pre- vs Post-Op Stereotactic Radiosurg	31-AUG-22	225	95
	NRGGY019	Ovar, Stg II-IV, Pac/Carb/Let vs. Let Mono	26-AUG-19	42	8
	NRGGY022	Mult Site/Stg, Carboplat Clearance Predict	18-NOV-19	0	1
	NRGHN005	HN, early stg P16-pos, randomize de-intensifi	10-JUL-19	380	125
	NRGHN006	HN, Erly Stg, Biopsy vs Dissection	08-JUL-20	206	71
	NRGHN009	HN, RT + HD Cisp vs RT + LD Cisp for SCCHN	27-OCT-21	256	105
	NRGHN010	HER2+ SGC, T-DM1 vs TH	30-SEP-22	150	47
	R1216	HN, Adv,Cis vs Dtx vs Dtx+Cetux	18-MAR-13	341	111
PREV	A212102	Blind Ref Set for Multicancer Early Detection	01-AUG-22	184	89
	EA1151	Prev, Tomosynthesis Mammographic Screening	06-JUL-17	232	95
	EA2185	Panc, Impact of Panc Cyst Surveillance	16-JAN-20	133	73
	EA8184	Pros, Dbl Blind GTC vs Placebo	20-MAY-21	67	36

**16-JUN-2024 6:11
OPEN STUDIES IRB REPORT**

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	NRGCC005	Colon,Non-AdvancedAdenomas, Colonoscopy5v10yrs	06-OCT-21	26	23
	NRGCC008	Ovar, BRCA1, non-inferiority of BLS vs BSO	23-JUN-20	317	133
SURV	A211901	Cancer survivors who smoke, txt cessation	01-DEC-21	113	47
SXQOL	S2010	ASPEN: Brst, Stg I-III, ASM vs Pt Ed	17-JAN-23	222	111
	S2205	ICE COMPRESS: Reduction of CIPN from Taxanes	16-MAR-23	14	30
	A222004	Mult, Olanza vs Megestrol for Anorexia	15-OCT-21	0	56
	ACCL1931	Leuk, All Stg, Levocarnitine Prophylaxis	14-AUG-23	33	13
	EAQ202	Improving AYA PROs in EA Trials	28-OCT-21	26	21
	NRGCC010	Endo, Stg I, LN Map for LE Limb Dysfunction	19-SEP-22	67	23
	NRGCC011	Breast, Survivors, Cog Training	02-FEB-24	45	18